Recently, anti‐IL‐6R antibodies have turned into the centre of interest for the treatment of autoimmune diseases such as rheumatoid arthritis (RA), systemic onset juvenile idiopathic arthritis (JIA), adult Still's disease and Castleman's disease 11. This evidence concerns the gene IL6R and rheumatoid arthritis.